Martin Shkreli (AP Images)

The FDA OKs gener­ic Dara­prim, the Mar­tin Shkre­li ther­a­py that trig­gered an un­end­ing tem­pest over drug pric­ing

The FDA post­ed a new gener­ic drug ap­proval Fri­day af­ter­noon, and this one ar­rived with a lit­tle ex­tra rel­ish added to the cus­tom­ary pro­nounce­ment.

The agency has giv­en Cerovene the green light to sell gener­ic Dara­prim, Mar­tin Shkre­li’s treat­ment for tox­o­plas­mo­sis that det­o­nat­ed a world class brouha­ha over drug pric­ing that has taint­ed the in­dus­try. Shkre­li no soon­er ac­quired the old, once cheap drug than he in­stant­ly raised the price by more than 5,000%, some­thing that the gen­er­al pub­lic — and a big seg­ment of the bio­phar­ma in­dus­try — was pro­found­ly ap­palled by.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.